Signos, a Burlingame-based weight care startup that combines continuous glucose monitoring with a data-driven recommendation app, is launching with $17M in funding.
This included a $13M Series A led by GV with support from Courtside Ventures, 1984 Ventures, and Tau Ventures, as well as Dexcom, a provider of glucose monitoring systems for diabetes management. Angel investors in the company include Larry Fitzgerald, Kelvin Beachum, and Jerod Mayo.
The company intends to use the funds to continue to expand operations and to reach general availability in early 2022.
Started in 2018 by Sharam Fouladgar-Mercer, Bill Tancer, William Dixon, and Pierre Wehbe, Signos provides a real-time glucose tracking system, bringing data-driven decisions to weight health.
The platform will help develop personalized answers to basic questions like what to eat, when to eat, and what exercises help encourage weight loss for each member. Signos combines a wearable continuous glucose monitor (CGM) with an AI-enhanced app to offer real-time data and recommendations designed to drive healthy and sustained weight loss. As members begin their Signos journey, they log what they eat, allowing the platform to learn each body’s reaction to specific foods. Once calibrated, the system uses that data to provide personalized nutrition suggestions, including which foods are best for each member, when to eat them and when to exercise to bring glucose levels back within their optimal weight loss range.
Today, the company is launching out of stealth mode with the opening of its platform to a limited number of customers and a partnership with Dexcom.
FinSMEs
10/11/2021